Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

As antibody-drug conjugates (ADCs) advance in precision oncology, diagnostics play a vital role in identifying eligible patients, validating biomarkers and supporting regulatory approval. A ...

Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

Lariocidin, a peptide made by bacteria living in soil, was effective against several different microbes responsible for deadly infections. UIC researchers working with collaborators at McMaster ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting ...

BioDuro has opened a new lab in Shanghai, China for highly potent compound synthesis at the hundred-gram scale.

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.